VolitionRX (VNRX) Projected to Post Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) will likely be announcing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.5190 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

VolitionRX Stock Performance

Shares of VNRX opened at $2.32 on Wednesday. VolitionRX has a one year low of $2.01 and a one year high of $18.80. The stock has a market cap of $18.77 million, a P/E ratio of -0.53 and a beta of 1.03. The stock has a 50-day moving average of $3.42 and a two-hundred day moving average of $5.07.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Citigroup downgraded shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. HC Wainwright decreased their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VNRX. Virtu Financial LLC purchased a new stake in VolitionRX in the 3rd quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRX in the second quarter valued at $52,000. Jane Street Group LLC acquired a new position in VolitionRX in the fourth quarter valued at $28,000. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX in the fourth quarter valued at about $34,000. Finally, Citadel Advisors LLC boosted its stake in shares of VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.